These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 29690784)

  • 41. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W; Louis E; Danese S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biosimilars of monoclonal antibodies in inflammatory diseases and cancer: current situation, challenges, and opportunities.
    Calleja-Hernández MÁ; Martínez-Sesmero JM; Santiago-Josefat B
    Farm Hosp; 2020 Apr; 44(3):100-108. PubMed ID: 32452309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
    Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
    Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe.
    Tsiftsoglou AS; Trouvin JH; Calvo G; Ruiz S
    BioDrugs; 2014 Dec; 28(6):479-86. PubMed ID: 25391420
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical trial development for biosimilars.
    Alten R; Cronstein BN
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.].
    Danesi R; Cremolini C; Ciccarone F; Lorusso D
    Recenti Prog Med; 2021 Jun; 112(6):444-453. PubMed ID: 34128936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating imbalances of adverse events during biosimilar development.
    Vana AM; Freyman AW; Reich SD; Yin D; Li R; Anderson S; Jacobs IA; Zacharchuk CM; Ewesuedo R
    MAbs; 2016 Jul; 8(5):861-6. PubMed ID: 27050730
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biosimilars: Exploring the History, Science, and Progress.
    Tariman JD
    Clin J Oncol Nurs; 2018 Oct; 22(5):5-12. PubMed ID: 30239529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulatory Approval Scenario of Biosimilars in Pediatric Patients in the United States and European Union.
    Radhakrishna S; Dahiya M; Pipalava P; Jose V
    Pharmaceut Med; 2021 Mar; 35(2):93-112. PubMed ID: 33595810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
    Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
    Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biosimilars: what the oncologist should know.
    Thill M; Thatcher N; Hanes V; Lyman GH
    Future Oncol; 2019 Apr; 15(10):1147-1165. PubMed ID: 30793950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim.
    Gascon P; Krendyukov A; Mathieson N; Natek M; Aapro M
    BioDrugs; 2019 Dec; 33(6):635-645. PubMed ID: 31440986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States.
    Xue X; Truong B; Qian J
    Expert Opin Biol Ther; 2023; 23(8):841-849. PubMed ID: 36892184
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.
    Dingermann T; Scotte F
    Expert Opin Biol Ther; 2016 Jul; 16(7):967-74. PubMed ID: 27227424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
    Schellekens H; Lietzan E; Faccin F; Venema J
    Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biosimilars: in support of extrapolation of indications.
    Ebbers HC
    J Crohns Colitis; 2014 May; 8(5):431-5. PubMed ID: 24594005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biosimilar regulation in the EU.
    Kurki P; Ekman N
    Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.